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The mechanisms bywhich the transition fkom asymptomatic 
left ventricular dysfunction tosymptomatic congestive h art 
failure occurs remain obscure. Contributiu to this transi- 
tion, however, is the development of sodium retention, 
which results from the inability of the body to excrete 
sodium at a rate commensurate with dietary sodium intake. 
This is associated with objective findiugs and subjective 
symptomsthatarethehailmarltofcoogestiveheartikihue. 
It is somewhat ironic that medicinal substances that could 
reduce sodium retention and edema (l-4) were ident&d 
before the publication f studies that characterized the reual 
aud neurohomumal f ctors that produce sodium reteution. 
Historically, diuretic m were approved for the treatment 
ofedematousdi8Kmlersife&acious&Mionofwei&tand 
improveduriuaryoutputcouldbedemous~,part.icularly 
a~~wereas~iatedwithalesseniagoSsymptoms. These 
eud poiuts are much less rigorous than the ekacy and 
s&y eud points that cumently exist fm approval of a new 
dnq for use in &atmeut of heart failure. in fwt, no 
currently app10ved diuretic drugs were primarily evaluated 
for the treatment of heart failure; rather, they were approved 
(JAmCo#CanW A]:IdYA-7IA) 
for the treatment of edema ssociated with congestive h art 
failwe. This is not a point of semantics. Large prospective 
trials of diuretic drugs in congestive heart failure have not 
been conducted. The ueed for such trials is mmpted by 
considerations such as the potential dverse ffect of diuretic 
ovenltilixaGoll, activatioll of neunIhormoual f ctors by so- 
dium depletion aud a paucity of data con&t@ pharmaccF 
kin tic,hemodynamicandcliuicaleffectsddiureticdnigsin 
controned trials of heart fake thempies. With recent ap= 
proval of newer d&tic wmpounds (9, coutimled assess- 
mentofthepokutialtherapeuticroledmodulatingatrial . 
natmmtkfactorandtbefavorableimptctofangiotensin- 
wnvertingenzyme iuhibitorsforthe treatmentofcongestive 
heartfailure,theappq&eroleaudusqgeofdiureticdrugs 
should be redefiued. 
lhMllHd_andN- 
characteristics of Congestive Heart Failure 
Uuder normal umditious, sodium exuetiou is governed 
bythreetMors.Firstaadmostimportautistheglome~ 
Wation rate (6,7). second is the level to which al- 
is increased, prod* sodium retention and potassium 
excretiou at the distal nephron (8-12). A “third factor” had 
beeupost&tedformanyyear!3,audresea=ho~~~ 
decade strongly sugpts that this is atrial ua@ketiC f;actar 
(13).ThereductioudglomenW6ltrationrate~~e 
heart failure is hi@y codated with henWdyRalUiC COldi- 
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tiollKthegreatertlle-dcardiacolltputalldlwlal 
bloodillniv,tllegeaterthe~of~6ltratioll 
rate(7).Thelapyfw~tivehuutfailurecantheoreti- 
cailyilm!aseglpmrmlaf8ltratiollrate,blltllocllrrent 
ttma&~lsenmlplwed renal hllctioll. Tile l-e 
-atthemacllladensa 
asansultofareductionof&mendar6lWkmrateisa 
potent stimulus ti r&n nlease. This is indepe&nt of 
lwlalnerves(alsoasepafatestimulusofreniusecretiou)aud 
is iadepeudent of local hemodynamic effects (14). Sodium 
cete&mis&reasedbyreniathroughthelatter’sproduc- 
tionof~II,whichisapotentrenalvasoamstrk+ 
tor,audisthepIimalysthuulusforal&stelXmesecMion 
(11,12). The eBct of IX& is a paradigm of the abmwmal 
lBlKohollnoMlmilieuthatalteKJreaalpeC&mlance.NauO- 
hormoMl&torsthatpromoteretelltionofsodiumand 
wateriuclude aldostenm, vasopressiu, a&o&& II, nor- 
ephlephrhleandthevasoco~~;incoo- 
tmst,prostacy&l,dopau&andatrialMtriWe&f&ctor 
favoWdium~.Thee&ctofvasoppessinispIimar- 
ilythepnwrotionof~waterntentian,ratherthallWdium 
Mention (11). Althou@ there is a correlrtiw d serum 
creathdneandbloodureauitrogenwith&uendarflltmtiou 
rate (measured by imdin clearance), it is dill?& to track 
individual function by serum arkers (7,ls). Reual blood 
nowandfuuctiontendtode~with~inuomlal 
s@iects(7).Thus,withthecombi&onofadvancedage 
aUdheart~,theexteutofrenalimpeirmentcanbe 
fiuther B (pig. 1) (7,15). 
SsdlmareteaWInlightofthe&ua&risticsjustra- 
viewed,itisnotsurprisingthatsodiumWentkmisa 
chaWWMcofcon@stiveheartfaihue.Patients 
whoarenotreceivingdiureticorvasodilatordrugscanbe 
class&d into those who achieve a neutral sodium balance 
aadthosewhoaresodiumretainiaginresponsetoa 
100_mEqsodiumintake(8).Althou&thesodiumandwater 
iutakeforthetwogroupsofpatientswassimilar,their 
responses were not. Sodium exuMion aud urinary volume 
wele both severely depressed iu the sodium-ret&iug pa- 
tients,whereasbl~uxeauitrogen,plasmareninactHy 
alldlUilNUyaldostefoneconcentrationWereallsislrjficently 
eleva&d. Patients iu neutral balauce xhibited relatively 
normalrenslfimction.Itmightbehypo&sMthatsodium 
MentionwasprcmotedbyillwXMtreninand~ 
activity; in addition, the p&mal absorption f sodium 
raducestheamouutoftubularsodium~hingthemacula 
denta ud consequently perpetuates activation f the &u 
system. Other factors uch as activatiou of sympathetic 
nervous system activity iu respouse toheart failure may 
coutriitetotheinabilitytoachieveneutralsodiumbalance 
after an oral sodium load (l&16,17). 
Heart Failum 
&tailed discllssiolls ofthe phamlacokinetics of diuretic 
druesin~stiveheart~~arebeyondthescopeofthis 
tiew aud have been presented lsewhere (18-23). Alter- 
ation of the pharmawkinetics andphafma&yaamics of 
furosemidewillbehighl@Wtoideutifythechangesthat 
occur in the heart failure process. Unique to the coucept of
diuretictherapyisthefactthattheurinaryconcentmtkmof 
thedrugdoesnotmmlyrellecteliminationofthecom- 
pound. The urinary concentration is the actual mount ofthe 
dru8 delivered to its primary site of action. Consequently, 
the mte of adminintration andblood concentration a&ct 
diWeticeffectiveuessoulytotheextentthattheyinlluence 
the delii of eRctive concentrations f dhuetic m to 
the lumen ofthe nephron tubule. The response todiic 
drugscaabealWedintwo~ways.F%st,apharma- 
cokiue&ef&tcanoccur,wherebytheactualconceuWon 
ofdiureticdrugthatreachesthetubularlumenisreduced, 
suchasdecreasedabso@onor~deliveryintothe 
renal tubule (ded @me&r Watiou rate). Sewud, a
pharmacoaynamic elTect caa occur, whereby the tar@ 
organrespuosetoagiveudng mtion is diminished. 
In this case, natrkuesis aud diuresis are diminished relative 
tothenormalrespuuse. 
The pbennaoolrinetics of intravenous furosemide ar  vir- 
tually unaltered iu congestive h art failure unless reu& 
dysl&tiou is siguiicant, as de&d by a creatiuine clear- 
ll= C30 mumin (24). Typically, this occurs ouly in mod- 
erate to severe chronic renal insul&iency and iu only the 
mostseverecasesofcollgestiveheart~(7).Thephar- 
. 
macoluneticsofomlfurosemidecanbealteredbytheheart 
faihuepmcessinthatabso@onmaybeprokmged,thereby 
delay& the time to ~andpeakconceatrationof 
JACC Vol. 22. No. 4 @y@ement AI 
October 1993:165A-71A DIURETIC THERAPY IN CONGESIIVE HEART FAZE 
167A 
hmnide within the urine (19-22). This e&d may also 
occur with bumetanide, butto a lesser degree, inview of 
better overall bumetanide absorption u der normal condi- 
tions (24). It may be argued that diirences between fir- 
rosemide and bumetanide ar not clinically relevant, as the 
response to treatment is measured by change-, in daily 
weight or net Sodium and water excretion. These pharma- 
cokinetic e&ct~ explain wby intravenouS furoSemide is 
Signi6cantly more e&ctive than oral Guosemide in the 
deco~nsated patient. The pharmaWynamic response to 
both intravenous and oral ftuosemide is altered in heart 
failure(22).ComparedwitbtherateofSodiumexctetionin 
normal st@cts, the rate in patientS with heart failure is 
reduced for any given renal tubular firrosemide concentra- 
tion. The ceiling dose of a loop diuretic drug in patients with 
heart faihue should be considered twice tbat in normal 
subjects in view ofthese changes (25). The pharma&inetics 
oftbiaxide iuretic drugs may also be abnormal in congestive 
heart failure. For instance, metolazone absorption can be 
substantially reduced, requiring Several days to achieve an 
adequate urinary concentration (26). 
Action and Adverse FAkcts 
~Sadlumr&ut&m.Theprimaryactionofdi- 
uretic therapy isto inueaSetheamountofSodiuminthe 
urine. This is accompanied by an increase in water excretion 
in a ratio that would maintain appropriate osmotic balance. 
An ideal diuretic drug would achieve this goal without 
altering additional electrolyte composition f the blood or 
urine and would not alter the neurohormonal milieu that 
uitimately controls rq&mal and systemic hemodynamics. 
This ideal diuretic drug &es not exist and remains the 
greatest driving force for the continued valuation f atrial 
. natmu&cfactor,whichapptuachesthisgoaItoagreater 
degreethancurrentdiureticdrugSthatblocknormalrenal 
tubularfunction.Thepotentialroleofatrialnatriureticfactor 
is discussed later in this mview. Of all diuretic drugs, the 
magnMeanddmationofdiureticresponsede&edinheart 
failure are best achieved by loop diuretic agents, where 
bIockadedsodiumttunsporta!clwssthetubuIarwauoftlle 
thickaScend@limboftheloopofHenleaccountSfortheir 
potent diuretic eEect (24). In mikler heart failure, athiaxide- 
type diuretic drug woukl be accep@le, particukuly com- 
bined witb a potassium-sparing gent. By common practice 
rather than theoretic considerations, ioop dir!retic agents are 
oftenpreferEdovertbethiaxidetype.TheclGcalleSpoDSe 
todiweticdrugs,incMingthatinpatientsti~h heartfaihue, 
haS been reviewed (3,18,23,25,27). 
VOWER DiureticdNgs 
are also believed to exert a hemodynamic eifect. This is 
charactetizedbyadecreaseincardiaciiUingpressureSandin 
caludated systemic vaScular reSiStaWe (28,29). sit&r lfa- 
wdilat@ properW have been sugge&ed by regional hemo- 
dynamic studies (30). It is po~tulated that this e&t is 
med&edbyareductionofar&riaIandintemtWsodium 
content. This vasodilating concept has Betsy C-W. 
Both acute and short-term therapy with diuretic drtqjs have 
alSO Suggested that diuretic therapy may have a vasocon- 
strictor e@ect (29,32). These con&ting observations my 
dkct diierences inpatient groups, everity ofdisease and 
conditions of study design. The cl&ally relevaut vapclllar 
characteristics of diuretic drugs may be better asses& in 
long-term rather than ~hort4erm studies. Inlong-term stud- 
ieS, diEerenceS in patient cbamcte&icS and the relative 
sodiumstatusatthetimeofstudywollldbemcwereadily 
wnttolled, yet such Studies are lacking. Although rewzsal of 
a vascular edema mechanic4 va~ocon~trictor effect cask be 
hypothesized for the va~odilatiug responSe to diuretic drugs, 
thevawconStrictore!fec&havebeenattriitedtoa&ation 
of neurohormonal factors, the most relevant being an in- 
crease inrenin system activity. This is reflected in plasma 
and urinary levels of renin, angioten~in II a d aldo~terone in 
both mild and Severe congestive h art faihue (S-10,16,17, 
29,32,33). Although furosemide therapy initiaky exerts a
favorable hemodynamic andreasl elfect, over subsequent 
days itmay be associated with activation fthe renin system 
(16,17,29). During this time, the initial improvement in 
cardiacoutputbecomeSattenuated.Adirect&mrenaletfect 
on the macula densa, ctivauon f the w control 
of renin release and diure&+induced volume contra&n 
ave all been proposed aspoGbie mechaniSmS for this 
stimulation f the renin system by fmosem&. Sodiim 
depletion will also increase markers ofsyiu@etic nervous 
system activity (8,16,17). Although concern hasbeenraised 
regard& these ffects, the magnitude of the neurobomumal 
response to diuretic drugs is not well e&Mshed in m 
ciinicai trials. Furthermore, theclinical ~i@icance ofthese 
cbangeSmaybeqwstionedinviewaf~pervasiveuseaf 
angiotensin-converting nzyme inhibitor therapy, which 
wouldattenuateorblocktheadverseactivationofnemohor- 
monal p thways. 
EMmQte~.ThegreatestadverSeefthctinpa- 
tientswithheaItfaikueremainsek?cuolytedepletiw.Di- 
llEtictherapYdaeSnot~calciumalldlMgneSiWl 
cleamuce~thedeShedSodiumcleamnce.MoStimuor- 
t ntIy, potassium cIeaumce by direct ub&u nte&+~~ 
and potassium for Sodium exchange produced by adverSe 
activation of akkuterone at t&e distal nephron (8,1633) 
~thegreatestc0a~inheartihihueandhavebeen 
imphcatedforarangeofclinicaladverSityfrummYalgies~ 
Sudden death produced by ventricular rhythmia% This 
concern is inten~iiied by concomitant administration of 
diixhl. 
Short- and Long-Term Therapy With 
DiuretkDrug!4 
shart~uw!npy. In~venDusdiuretictherapyisuseJ 
toacuteiytreatpulmonaryedemaandcardiacdecompensa- 
tionthathaSnotyetprogreSsedto~edemaand~ 
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a~~eugment&~inpatientsinwhomthediuretic 
~~~-ttWtnWtlth~iSattWtlatCd.hpllmo_ 
~dt3~th6obviousbwefitdacutc~therapyis 
thwapidclwranwofpubwnaryconge~~probablY~ 
~bynatkesisauddiuresis,avascukeif’ect,and 
reduction 0s httravascuk volume. Because heart faihue 
~~:~a-~* to *m 
deCOmpC1188fiOlW3undar 
tothektmentcfptthluqedema.Intravewusdiureuc 
thtxapytoallglnentdiuresiswhentheresponsetohmg-teum 
oralthuupyisattenuakdprovidesameanstOtreathtthe 
outpatient setting, thereby avoiding hospMzatkm. The 
mosturgentgoalofacutetherapyistbe4imifWionOf 
edema; however, potassium and magnesium suppkmetua- 
tionshouldbehMtuted.Usedathiazidetypcdiureticdrug 
in combination with a loop diuretk agent is uften very 
e#Ectiva (24,25,34,35). However, an uml tlliazide-type di- 
wetic drug, puticuMy nretolazoae, may require several 
days to achieve its maximal tkorable response asa result of 
altered phannscddaetics. The ability to utilize inuavenous 
. . chlorosiwpde(fixexample,Diuril)isoftenoverlwhed,but 
isaoexcellentappmachtocombinedthempywithaloop 
diuretic qgnt. Unlike hydrochIoroth&&, chlorotbiazide 
cpnbegivenintraveaouslyinadoaedW)toN)Omg,which . . 
is equivalent to a he d0SWf25tO50mg. 
Lapterm thempy. Traditionally, there has been acon- 
sensusinclini4practicethatdiurctkdrug3arethetherapy 
dchoiceinheartfaihueandrepreseutthemainstayof 
therapy iu most patients. A survey (35) amow both ospital- 
and oG&ased imernists and o&e-based cardiolo#ists 
lcve&dthat5396ofpbysiciansuseddiureticdrugsasinitial 
therapy for heart failmu in patients with normal sinus 
rhytbm;anadditiunal3O%usedacombinationofadiutetic 
druganddii.This-approachtothetreatment 
ofhearttkihlrcislihelytounde~leassessnu?ntwithgreater 
utilizstiondangioteasin~enzymeinhi~and 
as newer therapeutic appmaches emege. The severity d 
wdiumretcnthphdesaguidetuapprqktherapy 
CFable 1). When left veutricular dysfimctiun s asymptomatic 
andthereisnochnicalevidenceofsudiumrete&m,diurctic 
drugs may be withheld. However, all patients with heart 
faihueshouldbeinshuctedhtmodeuue&uuysahintahe 
(approximately 2 to 3 @day of sudium). This is often ne- 
#lecWt and excessive I ,tary sodium intahe wih readily 
ontwrmethethempc&e&ctofdiureticdrugs.Mainte- 
namz of contdcd dietary sodium intake will be necessary 
throushwt all stage8 dheart hike. Use of a thiazidetypc 
diuretiCdnyccanbeamsideredinpstientswithmildto 
moderate sodium ret&iott and normal renal function. AS 
sodhun retention progresses to a more q odetate rauge, a
roOp diuretic agent is indicated, with @stment for renat 
function if necessary. Inthe cquopr&Digouiu Mt&ice&r 
‘fM 0, however, patients inthe placebo (dimtic drug) 
llroup~WmatestrequiremeatfoPadditiddic 
dnrg~~Wueatestnumberofho@udadmi~ionsand 
eme@eltCy room visits. The initiation of au an&eu+ 
Tablel. kcommaMUscofDiuWicDrugsforCkgestive 
HealtFaaure 
c nverting enzyme inhibitor should also be considered at 
thii point. 
Diuretic drugs help minimize volume xpansion in pa- 
tients witb moderate to severe heart failure, thereby prevent- 
ing clinical deterioration. Once &rid retention becomes 
severe, a hi dose loop diuretic sgent combined with a 
thkidetypediureticdrugisoftenwatrantedaudmaybc 
given to@x with an a@otensin-convertintf enzyme inhib 
itor, unless this therapy iscontrahtdicated. CXcomxru with 
combined d&tic therapy iselectrolyte d pletion a d fur- 
ther hnpairmcnt of renal function. L&muory studies of 
ekctro~ytes and mnal timctional variables should be moni- 
tored.Shouldthecombiuatiouofaloopandthk&type 
diuretkdrugfailtoachievee&ctivediutusis,othermethods 
to consider include iutermittent intravenous administration 
~alloopdiuretic~,sholt-tmninfusionofaloopdiuretic 
age4ntoresc&tiondomlloop&auidccombkdthesapy. 
III the patient quiring a hospital stay, intravenous positive 
&tropic support isoften qtired. Although both ultraIll- 
tration and dialysis are e&We, they typically are neces- 
sary only when there is coexistent chronic tenal failure. 
Di~Drugsand w-m 
Enzyme Inhibitors 
The ongoing therapeutic success of the aogiotensin- 
cGnveltiugenzymeinhibitorswiuprompt~u~on 
afthisclassoftherapyandreisethequestioaafadhninish- 
ingroktbrdiuu%icdrugs.Itistheobservatiouiuboth 
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hypertension a d congestive h art failure that he magnitude 
of vasodiing response to angiotensin-converting enzyme 
inhibition is greater inthe presence ofsodium depletion (38). 
Angiotensin-converting enzyme inhibitors can favorably ef- 
fect the renal sodium excretion in response to furosemide 
(39,40). The relation of diuretic drugs to these agents as 
they affect renal excretory function is complex (40) and 
could be dependent on many factors including the dose of 
the angiotensin-converting enxyme inhibitor. Although the 
combination of a diuretic drug with an angiotensin- 
converting enzyme inhibitor provides excellent results, it is 
necessary to be alert to the risk of excessive hypotension 
and to either withhold the diuretic drug or reduce its dose 
should hypotension ccur (41). An additional practical point 
is whether spironolactone can safely be added to the com- 
bination of a loop diuretic agent and an angiotensin- 
converting enzyme inhibitor. One published study (42) and 
anecdotal reports uggest that this is feasible. However, 
additional longterm studies are required. The ongoing 
RALES Trial (spironolactone vs.placebo) will address this 
issue. 
Can Atrial Natriwetic Factor Be au 
Jzndogaous Diuretic Aged? 
Increasing the plasma concentration f atrial natriuretic 
i&or will stimtdate natriuresis, dimesis and vasod&ion 
and it has been suggested that these ifects would therefore 
make atrial natriuretic factor an endogenous diuretic agent. 
Two clh&ally relevant approaches have been attempted: 
administration of exogenous atrial nattiuretic factor and 
inhibition ofendogenous atrial nattiuretic factor degmdation 
through the use of neutral endopeptidase inhibitors. Admin- 
istration of exogenous atrial natriuretic factor eqtdres an 
intravenous route because atrial natrhuetic hctor is a peg 
tide that can be deg~M by the gastrointestinal tr ct during 
oral admit&ration. In patients with severe heart faihue, the 
renal response to atrial natriuretic factor is markedly dii- 
ished and tenin activity is not suppressed, probably because 
of the abnomml baseline conditkms of renal function (13). In 
contrast, with systemic ntravenous administration (13) and 
direct intraarterial administtation (43), the vasod&W elf&t 
ofatrialRatriureticfactorappearstobemaintainediuthese 
patients compamd with that in notmal subjects. However, 
atrial nattiuretic factor administration does not overcome 
the vasocon&ctor/sodium-remming influences of conges- 
tive heart faihne when heart Ghue is in advanced stages. 
Orally active aeutral endopeptidase hthiiitors permit an 
increaseinendogenousatrialnatriureticfactoronalong- 
term basis. Initial results with these compounds in severe 
heart failure do not suggest a sign&ant clinical dhuetic 
response. Ahhough exciting, the potential c htical impact of 
thesecompoundsisnotcertainbecausebase~atrial 
. 
natnmtic factor plasma levels in severe heart faihue are 
already5to10timesgreaterthanwrmal(13)andcanbe 
further increased by stimuli that increase atrial wall tension, 
such as exercise (40,44,45). The lack of renal and other 
target organ responses toincreased plasma trial natriuretic 
factor may be due to counterregtdatory effects of the renin 
system or to atrial natrituetic factor receptor dowtuegula- 
tion. 
clinical ‘hiab ofDiuretic Thempy: Are New 
lihctionsReq~? 
Currently available data suggest that there is an i&e. 
quatedatatweregadingthee&acyaadsafetyofdimtic 
drugs in patients with congestive heart failure. Because 
these compounds have previously been approved grimarhy 
for the treatment of edema in edematous disorders, the 
required end points were limited and generally consisted of 
weight reduction and increased urinary output. At issue is 
whether additional end points are requited. The dilemma is
that there is no single Womtory test that is a reference 
standard for sodium retention. Certahtly, many symptoms 
that constitute the New York Heart Association fun&nal 
classification a d other quality of lit% scores uch as dyspnea 
and exertional capacity may be limited by excess odium 
retention, yet symptoms are not specific. No single labora- 
tory test adequately reflects sodium retention. This is trued 
levels of serum electrolytes, indexes of renal function and 
measurement of plasma volume. The clinical decision that a 
patient is retaining sodium is based on the chnical manifes- 
tation of edema on physical examination. 
Attempts o ol.$ectQ these physical e&n Mings 
into a relative sccre may provide an index for sodium 
retention that could readily be applied to the evaluation of
newer agents with diuretic properties or to huge clinical 
trials.Anexampleofaproposedsodhunretentionsanethat 
wouldaddresstcisaeedisoutlinedinTable2.Thisscoreis 
based on the physical exam&&n Wings that routinely 
provide a clinical judgment for the presence ofedema nd 
sodium retention. Thus, the presemz of rales, peripheral 
pitting edema, weight change, hepatomegaly, third sound 
gaUopandincteasedjugtdarvenouspressmearefindingson 
examination that are routinely used by physicians. Rates and 
peripheral pitting edema re the most typicat gndiinss of 
sodium retention and are less likely to be obscured by 
coexistent anatomic considemtions. The extent ofmles and 
peripheral pitting edema can be further qWttiqed using 
reasonable anatomic guidelines.* Additional end points for 
the evaluation ofdiuretic drugs can be suggested (Table 3). 
Theseinchtdeutihxationofaqualityoflifescore,~ 
detailed ocumentation of sodium excretion, a requirement 
for improvement i  exercise capacity. RSSRSSmwlt of the 
extent o which neurohonnonal iuctom ate activated by 
diuretic therapy and more specigc documentation f the 
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systemieend~~vssc~~~~diureticdnyp.This 
issuemustberaisedatatimewhenmortalitystudiesare 
be&utilizedinalarlpepxqxMkmofcliniitrialsofheart 
Shire. 
Is a mtwtality study requhed f6r the assessment of 
did therapy? The question has been addmssed with 
digoxin therapy, which is also a long-standing therapy for 
heart Shue that is available in generic form. The evaluation 
odthenrortPlity&%tofdigHCin~debated~mlllly~ 
but is currclltly under evaluation in the D&in Invest@tor 
Group Ml (DIG). In view of the limited diuretic eflicacy 
d8ta base in congestive heart fkilure, the known adverse 
elkct of diuretic drugs on electrolyte balance and the poten- 
tial fbr neurohormonal activation by diuretic m, large 
clinical trials including the possibility of a mortality end 
point should be considered fordiuretic drugs. 
Currently, there an no large scale prospective pkbe 
contiled trials ofdimetic drugs in congestive h art failure. 
The CaptoprSDigoxin Multicenter T ial (37) provkks in- 
sights rega&g the e&cts of diuretic drugs in moderate 
heart Mure. In that study, the placebo arm of therapy 
involved a group ofpatlents receivif~ diuretic drugs alone. 
The increased rate of hospital dmissions and emerge~y 
room visits and the increased requirement foradditional 
diuretic therapy within that group compared with either the 
qtopril or digoxin group (37) raise concern regarding 
diuretic drugs as monotherapy for heart failure. However, 
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